Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Niki BioSolutions, Inc.

NIKINASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Oct 21, 2026Accepted Oct 21, 2026, 4:50 PM EDTFiling CIK 1734005Accession 0001213900-26-111383
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-07-22
Issuer
Niki BioSolutions, Inc.
Issuer CIK
0001734005
Trading symbol
NIKI

Reporting owner 1

Name
Sheinerman Kira
Reporting owner CIK
0001438091
Relationship
Director · 10% owner
Address
116 VILLAGE BOULEVARD, SUITE 200, PRINCETON, NJ, 08540

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Options8.832026-07-22A · Form 48,000A0[F1]2036-07-22Common Stock8,0008,000D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
The options vest as follows: (i) 2,000 options vested immediately upon the closing of the merger; and (ii) the remaining 6,000 options vest in three equal quarterly installments of 2,000 options each, commencing on the first business day of the first full quarter following the effective date of the merger.↩ 1

Signature 1

Signed
/s/ Kira S. Sheinerman
Date
2026-10-21

Company context

Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.

Current securities

Historical securities (1)

Recent company filings

  1. 4 filingOct 21, 2026
  2. 4 filingOct 21, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 13, 2026
  4. EFFECT filingOct 9, 2026
  5. Entry into a Material Definitive AgreementOct 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.